21:41 , Jul 25, 2019 |  BC Innovations  |  Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...
21:03 , Jun 3, 2019 |  BC Extra  |  Preclinical News

June 3 Preclinical Quick Takes: 'CRISPR baby' gene mutation increases mortality; Axial's microbiome for autism

CCR5 mutation linked to increased death rate  Using genomic and health data from over 400,000 individuals in the UK Biobank, University of California Berkeley researchers found that homozygous Δ32 mutations in CC chemokine receptor 5...
20:08 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
13:00 , Feb 27, 2019 |  BC Extra  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
02:12 , Dec 1, 2018 |  BioCentury  |  Politics, Policy & Law

China’s germline growing pain

How Chinese regulatory authorities respond over the long term to the CRISPR baby furor could influence its industry’s success on the global stage, as domestic and international stakeholders seek reassurance that the authorities are on...
22:20 , Oct 31, 2018 |  BC Innovations  |  Translation in Brief

Programming cell circuits

Two synthetic biology teams have developed methods to regulate cell behavior at the protein level using viral proteases. The work could aid the development of conditionally activated cancer therapies that bypass the risk of insertional...
23:34 , Oct 3, 2018 |  BC Extra  |  Politics & Policy

Phage display founders win Nobel for chemistry

The 2018 Nobel Prize for Chemistry was awarded to three scientists for their work on directed evolution of proteins and enzymes, which led to the development of human antibody-based therapeutics. The first, Humira adalimumab from...
20:11 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three...
21:18 , Jul 31, 2018 |  BC Innovations  |  Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...